JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J. Biol. Chem., Vol. 275, Issue 24, 18302-18310, June 16, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ricciardi, A.
Right arrow Articles by Ducancel, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ricciardi, A.
Right arrow Articles by Ducancel, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Do Structural Deviations between Toxins Adopting the Same Fold Reflect Functional Differences?*

Alejandro RicciardiDagger §, Marie-Hélène le Du, Mounira Khayati, Federico DajasDagger , Jean-Claude Boulain, André Ménez, and Frédéric Ducancel§

From the Dagger  Instituto de Investigaciones Biologicas, Clemente Estable, Montevideo, Uruguay 11600 and the  Département d'Ingénierie et d'Etudes des Protéines, Commissariat à l'Energie Atomique, CE Saclay, 91191 Gif-sur-Yvette Cedex, France

Received for publication, September 24, 1999, and in revised form, December 17, 1999

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Three-finger proteins form a structurally related family of compounds that exhibit a great variety of biological properties. To address the question of the prediction of functional areas on their surfaces, we tentatively conferred the acetylcholinesterase inhibitory activity of fasciculins on a short-chain curaremimetic toxin. For this purpose, we assimilated the three-dimensional structure of fasciculin 2 with the one of toxin alpha . This comparison revealed that the tips of the first and second loops, together with the C terminus residue, deviated most. A first recombinant fasciculin/toxin alpha  chimera was designed by transferring loop 1 in its entirety together with the tip of loop 2 of fasciculin 2 into the toxin alpha  scaffold. A second chimera (rChII) was obtained by adding the point Asn-61 right-arrow Tyr substitution. Comparison of functional and structural properties of both chimeras show that rChII can accommodate the imposed modifications and displays nearly all the acetylcholinesterase-blocking activities of fasciculins. The three-dimensional structure of rChII demonstrates that rChII adopts a typical three-fingered fold with structural features of both parent toxins. Taken together, these results emphasize the great structural flexibility and functional adaptability of that fold and confirm that structural deviations between fasciculins and short-chain neurotoxins do indeed reflect functional diversity.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Three-fingered folded proteins are abundant in venoms of Elapid and hydrophiid snakes, and are capable of performing a large number of refined highly toxic functions (1). Snake toxins with such a fold are usually classified as short-chain toxins, with about 60 residues and 4 disulfide bonds, and as long-chain toxins, with ~70 residues and 5 disulfide bonds. Typical members of three-fingered toxins include short-chain curaremimetic toxins (2), long-chain curaremimetic toxins (3, 4), which block peripheral nicotinic acetylcholine receptors, neurotoxins (5, 6), which act on neuronal receptors, muscarinic toxins, which activate or block muscarinic receptors (7), and fasciculins, which inhibit acetylcholinesterases (8-10). The abundant literature on the structures of three-fingered toxins indicates that their fold is composed of a globular core with four disulfides and three fingers that emerge from the core. It has been suggested that the primary function of the core is to maintain the overall structure of this family of toxins (11, 12), whereas a structural plasticity is perceived at the level of the loops (13). The latter might allow functional residues in different active toxins to adopt a variety of arrangements to recognize their targets (14, 15). Close inspection of individual three-finger structures reveals that they display marked differences from one toxin to another, indicating that this fold can indeed accommodate some deviations. Thus, the first loop is longer in short-chain than in long-chain curaremimetic toxins, and long-chain toxins possess an extra loop cyclized by a disulfide bond localized at the very tip of the central loop (2). In muscarinic toxins, the tip of the central loop is more twisted than in a short-chain curaremimetic toxins (7). The orientations of the loops relative to the plane defined by the sheet characteristic of three-fingers toxins can also vary from one toxin to another (15). Finally, the fold acts as a monomer in most toxins or as a dimer in neuronal toxins. It is currently speculated that these structural deviations reflect distinct functions, and indeed this hypothesis recently received some support. Thus, it has been demonstrated that the capacity of long-chain curaremimetic toxins to recognize the alpha 7-type neuronal acetylcholine receptor with high affinity, is depending on the presence of an extra cyclic loop at the tip of their central loop (16).

The aim of this paper was to explore the possibility that other structural deviations, more subtle than the presence of a cluster of additional residues, could also reflect the localization of a particular functional topography. To investigate this hypothesis, we searched for structural deviations between two functionally unrelated three-fingered toxins: a short-chain curaremimetic toxin that blocks acetylcholine receptors (17), and a fasciculin known as acetylcholinesterase blocker (18). The biological determinants of these two toxins were recently shown to be located within the same area of the three finger fold but on opposite faces (15). An exhaustive mutational analysis revealed that a short-chain neurotoxin recognizes the nicotinic acetylcholine receptor via a homogenous and polar surface of 10 residues located on one face of the toxin (19, 20). In contrast, the three-dimensional structures of two fasciculin 2 AChE1 complexes revealed a three point anchorage forming a large contact area located on the other face of the toxin and involving a majority of main-chain/side-chain hydrophobic interactions (21, 22).

We investigated the possibility of generating acetylcholinesterase inhibitory activity within the host curare-like toxin alpha  through the progressive transfer of the most structural deviating regions from fasciculin 2. We show that the host protein cannot only accommodate the imposed structural modifications but also that the biological activity of the host short-chain toxin vanished, whereas nearly all the acetylcholinesterase-blocking activities of fasciculins emerged in a chimeric protein. The three-dimensional structure of the most active chimeric compound we engineered reveals a typical three-finger fold among which only transferred regions adopt a fasciculin-like conformation. Taken together, these results strongly suggest that structural deviations and functional topographies are intimately linked to each other. They also emphasize the great structural flexibility and functional adaptability of the three-finger fold. We propose this approach as a convenient alternative to systematic mutations in predicting a functional determinant at the surface of a toxin adopting a three-fingered scaffold. The evolutionary implications of these findings will be discussed.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Genetic Constructions-- DNA fragments encoding recombinant fasciculin 1 (rFas1) and chimeric Talpha /Fas proteins, named rChI and -II, were cloned into the bacterial expression vector pCP (23) and expressed as fusion proteins with two synthetic IgG binding domains derived from protein A (24). Extremities of the cDNA encoding fasciculin 1 were conveniently modified by polymerase chain reaction amplification to allow its orientated cloning. The synthetic genes encoding the two chimera were derived from that initially built to express the native toxin alpha  from Naja nigricollis (23) using the primary structures of native toxin alpha  and fasciculin 2 (Fig. 1A). Briefly, the strategy for assembling the genes was as follows: first, 100 pmol of 12 complementary oligonucleotides with sizes ranging from 17 to 48 bases, covering both strands and using high frequency codons in Escherichia coli, were annealed together; second, semisynthetic genes were generated after ligation together of the three N and C terminus cassettes, respectively, and third, semisynthetic genes were gel-purified and covalently associated. The cDNA and the two synthetic genes have at their 5'-extremities a KpnI restriction site followed by a sequence encoding residues Asp-Asp-Asp-Asp-Lys specifically recognized by the bovine enterokinase. Two tandem stop codons TAA and a BamHI restriction site were created de novo at the 3'-extremities (Fig. 1B). Finally, correctness of these constructions was checked by DNA sequencing of both strands.

Expression and Purification of Fused Proteins-- E. coli BL21(DE3)LysS was used as a host strain for the expression of ZZ-Fas1 and ZZ-Talpha /Fas I and II. For this purpose, an overnight culture of freshly transformed cells was used to inoculate 500 ml of tryptic soy broth (Difco, Detroit, MI) supplemented with glucose (5 g/liter), ampicillin (200 mg/l), and chloramphenicol (30 mg/l). Induction of hybrids production was initiated by the addition of 0.1 mM (final concentration) isopropyl-beta -D-thiogalactopyranoside when the optical density of the culture incubated at 37 °C under aeration reached 0.5-0.6 at 600 nm. After 3 h of induction (A600 = 1.8-2.0), cells were harvested by centrifugation, resuspended in 50 ml of TSE buffer (30 mM Tris-HCl, 20% sucrose, 5 mM EDTA, pH 8) supplemented with 0.1 mM of phenylmethylsulfonyl fluoride (final concentration), and disrupted by sonication at 0 °C, 5 × 3 min at 60% of full power. The supernatant was first purified on an IgG-Sepharose 4B-column (Amersham Pharmacia Biotech) according to Drevet et al. (23). Lyophilized hybrids eluted from the IgG column were further purified by chromatography on a reverse-phase HPLC column (Vydac, C4 semipreparative) equilibrated in 0.1% trifluoroacetic acid. Elution was performed using a 0.1% trifluoroacetic acid/CH3CN/H2O gradient of 0-60% in 60 min. Protein concentration was determined spectrophotometrically, based on the following calculated extinction coefficients at 278 nm: epsilon M = 6200, 7500, and 8800 cm-1 for ZZ-ChI, -ChII, and -Fas1, respectively.

Bovine Enteropeptidase Cleavage and Renaturation of Recombinant Proteins-- 1 mg of ZZ fusion protein purified as described above was combined with bovine enteropeptidase (Invitrogen, EKMax grade, specific activity = 8.500 units/ml) in 50 mM Tris, pH 8, 10 mM CaCl2, 1% Tween-20, in a total volume of 0.83 ml, at an enzyme:substrate ratio of 1:19,000 (w/w) and incubated at 37 °C for 3 h. Resulting rFas1 or Talpha /Fas chimeras were directly chromatographed on a reverse-phase column (Vydac, C18) using the following gradient: 0-5 min in 0.1% trifluoroacetic acid, 5-30 min to reach 24% of CH3CN, 10 min in trifluoroacetic acid, 0.1%/CH3CN 24%, and finally 40-70 min to obtain 60% of CH3CN. Products were analyzed on 20% polyacrylamide gel and submitted to amino acid composition and Edman degradation for peptide sequencing. In vitro renaturation of unfolded proteins was performed overnight at room temperature in a final volume of 1 ml using the following buffer: 0.1 M phosphate buffer, pH 8, containing 4 mM GSH and 2 mM GSSG. Refolded compounds were finally purified using conditions similar to those previously described. The dichroic spectra of refolded compounds were recorded at 20 °C using a CD VI Jobin-Yvon dicrograph, at a protein concentration of 5 × 10-5 M.

Radioimmunoassay and Inhibitory Activities-- The radioimmunoassays were carried out as described previously using 3H-labeled toxin alpha  and two toxin-specific monoclonal antibodies, i.e. Malpha 1 and Malpha 2-3 (25). Electrophorus electricus electroplax acetylcholinesterase (EeAChE) and human butyrylcholinesterase were used to assess the inhibitory activities of rFas1, rChI, and rChII. AChE activities were spectrophotometrically measured using acetylthiocholine (1.0-0.06 mM) as substrate and 0.3 mM 5,5'-dithiobis(2-nitrobenzoic acid) as chromophore in 50 mM phosphate buffer, pH 7.5, 0.1 mg/ml BSA (26). Assay mixtures (including the different inhibitors) were preincubated for 60 min at 37 °C before starting the reaction by the addition of acetylthiocholine. Ki values of rChII and native fasciculin 2 were estimated from Dixon plots as previously reported (27-29). The lower Ki value of rChI was estimated from slopes and intercepts of reciprocal 1/v Lineweaver-Burk plots versus various chimera I concentrations. Human BChE activities were assayed in 50 mM phosphate buffer, pH 7.5, 0.1 mg/ml BSA at 37 °C with butyrylthiocholine (BTCh) as substrate, after a preincubation of 10 min. Hydrolysis of 1 mM BTCh was followed spectrophotometrically. Type and inhibition constants of BuChE for recombinant chimera II were determined either using Dixon plots 1/v versus inhibitor concentration or according to Cornish-Bowden (30) by plotting S/v against S, at three BTCh concentrations: 0.13, 0.25, and 0.50 mM.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Structural Characteristics of Short-chain Curaremimetic Toxins and Fasciculins-- To examine the structural homogeneity of these two toxin families, we compared the x-ray three-dimensional structures of representative members using the iterative program ALIGN (31). Curaremimetic toxins clearly form a homogenous structural family, with a calculated average r.m.s. calpha deviation value of 1.2 Å. However, the tips of loop 1 (residues 7-12), of loop 2 (residues 29-35), and the two C-terminal residues deviate by between 3 and 5 Å (not shown). It is noteworthy, that six of the ten functional residues forming the toxic site of this famility of toxins are located in the two most variable regions (19, 20). It has been suggested that the flexibility of the tip of loops 1 and 2 is necessary to fit the nicotinic acetylcholine receptor (32).

Fasciculin 1 and 2 from the venom of the green mamba Dendroaspis angusticeps are two potent inhibitors of acetylcholinesterases (8) whose high resolution three-dimensional structures have been solved using x-ray crystallography (9, 10). Their amino acid sequences differ only by a single substitution at position 47, where a tyrosine or an asparagine is found in fasciculin 1 and 2, respectively (33). Superimposition of their backbones reveals r.m.s. calpha deviation values mostly comprised between 0.3 and 2 Å. Only residues 6-13 of loop 1 have distinct conformations with r.m.s. deviations ranging between 2 and 10 Å (not shown). It has been proposed that this unusual loop flexibility might be important in the binding to AChEs. Interestingly, elucidation of the x-ray structures of two fasciculin 2 AChE complexes shows that the conformation of the free fasciculin 2 resembles that of the bound state and differs from that of free fasciculin 1 (21, 22). Taken together, these data support the idea that loop 1 in fasciculins displays considerable mobility, which is important for tight binding to AChEs. The identification of interacting residues at the tip of loop 1 further emphasizes its functional importance. Even if characterized by a similar fold, curaremimetic toxins and fasciculins therefore possess a number of specific structural features.

Structural Deviations between Short-chain Curaremimetic Toxins and Fasciculins-- To identify precisely the regions where these structural deviations occur, we carried out a detailed structural comparison of toxin alpha  from Naja nigricollis, a typical member of short-chain toxins (34, 35), and fasciculin 2. Though both toxins possess 61 residues, toxin alpha  and fasciculin 2 each differ by a specific insertion, which causes a numbering shift from position 18 that is only restored at position 56 (see Fig. 1). Using the iterative program ALIGN, we performed a superimposition of the backbone of the x-ray structure of fasciculin 2 and toxin alpha  (Fig. 2, lower views), revealing an average r.m.s. deviation of 2.82 Å for 226 of the 244 atom pairs of the backbone used. The best superimpositions include most of the major beta -sheet strands: 3-5, 14-17, 23-26, 34-41, and 49-55, together with the turn linking loops 2 and 3, and the upper part of loop 3, which includes residues 56-60. However, distances greater than 2.0 Å were observed for regions 5-12, 18-21, 27-34, 41-47, 50, 55-56, and 61 (Fas numbering). Therefore, the regions with the largest structural deviations between toxin alpha  and fasciculin 2 correspond to almost all of the first loop, the following turn, the lower part of the second loop, and the C terminus residue. Interestingly, except for segment 18-21, the functional residues of these two molecules are included in these areas. That segment 18-21 did not superimpose well is not surprising because it corresponds to the turn connecting loops 1 and 2, where the additional proline +18 in toxin alpha  is located. The deviating region 5-12 forms a beta -hairpin at the tip of loop 1 of both toxins. However, their primary structures are totally different resulting in highly distinct organizations in the two toxins, the hairpin looks longer in toxin alpha  and broader in fasciculin 2 (Fig. 2). Amino acid residues 27-34 constitute the largest deviating region with a maximum distance of 12 Å for calpha 31. This second beta -hairpin localized at the extremity of the central loop displays opposite orientations in the two toxins, inducing an inversion of their overall concavity (Fig. 2). Thus, the fine comparison of the structures adopted by fasciculin versus toxin alpha  reveals three significant structural deviating regions corresponding to the tips of loops 1 and 2 together with residue 61. 


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   A, sequences of the natives toxin alpha  from N. nigricollis and fasciculin 2 from D. angusticeps and the newly designed toxin alpha /Fas2 chimera. Cysteine residues are underlined. The additional proline residue between toxin alpha  and chimera as compared with fasciculin 2 is bold. Substituted residues are in italic. Asterisks indicate the two cis-prolines found in fasciculin 2. B, deduced amino acid and designed nucleotide sequences encoding the toxin alpha /Fas2 chimera II. The position of the 12 oligonucleotides is shown by bold slashes. Substituted sequences are underlined. Numbering refers to amino acid positions. 5'- and 3'-KpnI and BamHI half-restriction sites used for cloning are shown. The enterokinase recognition sequence and stop codons are indicated in thick and bold characters, respectively. C, sequence alignment of fasciculin 2 (Fas 2), rChII (Chim), and toxin alpha  (Tox alpha ). Residues of rChII provided from fasciculin 2 are in yellow. Residues of rChII provided from toxin alpha  are in blue. Residues conserved between fasciculin 2, toxin alpha , and rChII are in green.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   Monographic comparison (upper panels) and superposition (lower panels) in ribbon representation of the three-dimensional structures of toxin alpha  (blue) and fasciculin 2 (yellow). Characteristic beta -sheets are indicated as large arrows. The two models were superimposed by using the topologically equivalent Calpha S contained in the three-stranded beta -sheet. Differences in loop 1 organization and loop 2 orientation are shown on the front (lower left) and 90° rotated (lower right) views, respectively.

Design of Chimeric Proteins-- A first chimera (ChI) was designed by transferring in toxin alpha  the two major deviating regions 5-12 and 27-34 from fasciculin 2 (Fig. 1). As deduced from the above comparison plus the sequence alignment, these two sequences belong to the first and second loops. Moreover, it is known that the adjacent residues of an amino acid sequence region are often critical for this stretch to adopt the expected secondary structure (36). In addition, the structure superimposition revealed conserved residues surrounding the deviating regions (Fig. 1), possibly playing the role of hinges to naturally accommodate the transferred segments into the host toxin. Therefore, to preserve both the beta -sheet and the loop flexibility, we transferred the loop 1 in its entirety, together with residues 27-37 (toxin alpha  numbering) in the first construction (Fig. 1). To further attenuate the structural deviations between the two toxin conformations, we designed a second chimeric construction (Fig. 1). In the latter, we additionally substituted the C-terminal asparagine residue of toxin alpha  for a tyrosine. This was motivated by the observation that within the complex formed with AChE, the C terminus of Fas2 is stabilized by Tyr-4, inducing a substantial increase of the interface (21). By doing this, we anticipated that all residues involved in the stabilizing intramolecular hydrogen bonding between both loops 1 and 2 and the C terminus of native fasciculin 2 may be correctly transferred. We therefore designed two recombinant chimeric proteins, rChI and rChII, by substituting into toxin alpha  41 and 42, 6% of fasciculin 2 residues, respectively. Among the 45 remaining amino acid residues of rChII, 13, the four pairs of cysteine residues, Tyr-23, Arg-37, Gly-38, Pro-42, and Asn-59, have been described as forming the core responsible for the common three-fingered architecture (13), 15 are specific to short-chain curaremimetic toxins, and 21 are common to both toxin families.

Production, Folding, and Purification of Recombinant Fasciculin 1, rChI, and rChII-- Three reasons motivated our choice to express fasciculin 1 instead of 2 as reference for this study. First, prior to this work we cloned the cDNA encoding fasciculin 1 (33); second, both AChE inhibitors display very similar biological activity (8); and third, the single difference between fasciculin 1 and 2 is located at position +47, a region of short-chain origin within the two chimera we designed. Recombinant native fasciculin 1 and chimera I and II were produced within the bacterial cytoplasm fused to two synthetic IgG binding domains (24). This recombinant system was previously proved to be highly efficient for producing small proteins rich in disulfide bonds (23) and recently to generate recombinant toxoids (37). It offers the double advantage of maintaining hybrids in a soluble form and rendering their purification from bacteria lysates easy by IgG affinity chromatography. Fig. 3, lanes 2 and 3, shows an SDS-polyacrylamide gel electrophoresis analysis of an IgG-Sepharose eluted fraction of a lysate obtained from bacteria transformed with plasmids encoding the fused chimera I or II, revealing identical profiles. Each IgG-purified recombinant ZZ-chimera appears as a major band, migrating with an apparent molecular mass close to the expected 24 kDa. A similar value was noted for the ZZ-Fas1 hybrid (not shown). Furthermore, the ZZ-Fas1 or ZZ-chimera hybrids were stable in the bacterial cytoplasm because no low molecular weight product was detected on the gel (Fig. 3). After an additional purification step on reverse-phase HPLC chromatography, 70-90 mg of ZZ-fusion toxins were obtained/liter of bacterial culture, which is about 100 times higher than yields achieved using the secretion vector pEZZ18 (19, 38-41).


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 3.   SDS-polyacrylamide gel electrophoresis analysis of recombinant chimera production, cleavage, and purification. Crude bacterial extract of BL21(DE3)LysS transformed by pCPZZ/ChII (lane 1). ZZ-ChI or -II hybrids after IgG chromatography purification (lanes 2 and 3, respectively). Crude enterokinase cleavage profil of purified ZZ-ChII hybrid (lane 4). Reverse phase HPLC-purified recombinant chimera II (lane 5). High molecular mass (H) markers were: 97, 66, 45, 31, 21.5, and 14.4 kDa (Bio-Rad). Low molecular mass (L) markers were: 16.9, 14.4, 8.2, 6.2, and 2.5 kDa (Amersham Pharmacia Biotech).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of E. electricus AChE. The inhibition induced by different inhibitors was measured after 60 min at 37 °C as described under "Experimental Procedures." Data points correspond to duplicates that differed by less than 5%. black-square, fasciculin 1; triangle , recombinant fasciculin 1; , fasciculin 2; , chimera II; open circle , chimera I; black-triangle, unfolded chimera II.

The presence of two methionine residues at positions +2 and +33 or +34 in native fasciculin 1 or rChI and -II, respectively, excluded the use of CNBr to cleave ZZ hybrids as described previously (42, 43). To circumvent this problem, we introduce the recognition sequence "DDDDK" for the bovine enteropeptidase, which cleaves specifically after the P1 lysine residue (44). However, because of problems of efficiency and specificity of cleavage probably because of the presence of contaminating serine proteases, we finally used a cloned bovine enterokinase catalytic subunit, an enzyme described as having a higher specific activity (45). As a result, cleavages of recombinant ZZ fusion proteins were achieved almost to completion, whatever the toxin moiety. This is illustrated in the case of chimera II in Fig. 3 (lane 4), where two major products are visible with an apparent molecular mass of 14 and 7-8 kDa, corresponding to those expected for the ZZ domains and cleaved chimera, respectively. The recombinant proteins were purified by reverse-phase HPLC, leading to a homogeneous moiety as shown in Fig. 3 (lane 5). Sequencing of the first 15 amino acid residues and amino acid analysis of the recombinant proteins, confirmed the specificity of the cleavage and the absence of any side product (not shown). On average, we obtained 10-14 mg of each cleaved and purified recombinant protein/liter of bacterial culture.

Owing to the strategy of expression, disulfides bridges of unfolded native or recombinant fasciculin 1 and chimeric recombinant polypeptides were formed in vitro using similar redox conditions. The most appropriate conditions to refold reduced native fasciculin 1 (nFas1) required a ratio of 4 GSH:2 GSSG. Under these conditions, the refolded fasciculin 1 recovered full inhibitory activity toward acetylcholinesterase (not shown), whereas its reduced and carboxymethylated form was inactive. The same conditions were found to be most appropriate for the rFas1 and both chimeric proteins. No further improvement was seen in the presence of enzymatic catalysts such as protein disulfide isomerase, alone or in combination with thioredoxin (data not shown). No free thiol group was detected in either recombinant product, using Ellman reagent, indicating that the 8 cysteines were involved in disulfide bridges. We noted no difference between the refolding capacities of the recombinant fasciculin 1 and the chimera as compared with the native fasciculin 1. It is noteworthy that the refolding conditions we used are opposite to those used to refold toxin alpha  (23), with GSSG/GSH ratios of 2/4 versus 4/2, respectively. This was surprising, because rChI and -II contain the globular core where the disulfides of toxin alpha , a region which has been several times associated with conformational features of the short-chain three-fingered fold and in particular with its folding rate efficiency, are located (46). This suggests that the role played by the upper part in the folding of short-chain toxins might be influenced by sequence variations in the two first loops, and/or that at least one of the four intramolecular disulfide bonds within these three recombinant compounds might be characterized by a higher redox potential.

Secondary Structure, Antigenic, and Functional Properties of Recombinant Fas 1 and Chimeras I and II-- Refolded recombinant fasciculin 1 and chimeras I and II display similar far-UV CD spectra indicating that they have similar secondary structures, which are absent in reduced/carboxymethylated rChII (not shown). Furthermore, the simultaneous presence of a positive band around 197 nm and a negative one at 215 nm, both absent in denatured chimera II, strongly suggests that the dominant beta -sheet structure characterizing the three-finger-like fold was present in the two recombinant chimeric proteins. Native toxin alpha , which naturally interacts with high affinity with the nicotinic acetylcholine receptor (47), is also specifically recognized by two anti-short-chain neurotoxins: monoclonal antibodies called Malpha 1 (48) and Malpha 2-3 (49). However, the molecular topographies recognized on the surface of short-chain neurotoxins by Malpha 1 (50), Malpha 2-3 (51), and the receptor (19, 20, 51) have been deeply altered to design rChI and -II. Thus, as expected, competition binding experiments with tritiated toxin alpha  demonstrated that in contrast to the wild-type toxin alpha , neither of the two chimera was able to bind anymore to either monoclonal antibodies or to the acetylcholine receptor, even at concentration as high as 10 µM (not shown).

Fig. 4 shows the inhibition patterns of AchE from EeAChE by increasing concentrations of nFas1 and -2, rFas1, and rChI and -II. More precisely, the data demonstrate that: i) rFas1 has a similar inhibitory activity as compared with nFas1 or nFas2; ii) rChI inhibits hydrolysis of acetylthiocholine with an IC50 value approximately 150-fold higher than that of native fasciculins; iii) rChII is only 15-fold less potent that native fasciculins; and iv) reduced/carboxymethylated rChII has virtually no activity at concentrations nearly four orders of magnitude greater than the lowest active concentration of native fasciculin. To gain a more precise view of the relative potencies of these compounds that act as tight inhibitors (28), the data have been represented in typical Dixon (Fig. 5) and Lineweaver-Burk (Fig. 6) plots. The Ki values thus calculated are respectively equal to 5500, 680, 38, and 42 pM for rChI, rChII, rFas1, and native fasciculin 2. Lineweaver-Burk representations (Fig. 6) also demonstrate that chimeras I and II are noncompetitive inhibitors of EeAChE, suggesting that both compounds bind to the peripheral site of the enzyme as do native fasciculins (29). Finally, we studied the effects of our two recombinant chimeras on hydrolysis of BTCh by human butyrylcholinesterase. As shown in Fig. 7, upper panel, human butyrylcholinesterase was inhibited dose dependently by rChI and rChII in the micromolar range, with an IC50 value slightly increased as compared with nFas2. The type of inhibition of human BuChE by the most potent chimera rChII, and its constant, were determined according to the methods of Dixon (27) and Cornish-Bowden (30). The intersection points of the plots of S/v (Fig. 7, lower left panel) or 1/v (Fig. 7, lower right panel), as a function of varying concentrations of rChII, reflect the dissociation constants of the EI complex (Ki) and ternary complex ESI (Ki'), respectively. We therefore conclude that rChII is a mixed or a noncompetitive inhibitor of human butyrylcholinesterase with Ki and Ki' values of 1.27 and 1.13 µM, respectively. These results are in agreement with those reported by others (52).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Dixon plots with data from E. electricus AChE inhibition by native fasciculin 2 and recombinant chimera II. Activities were measured in 1-ml reaction mixtures containing 50 nM phosphate buffer, pH 7.5, 0.1 mg/ml BSA, and 0.32 mM 5,5'-dithiobis(2-nitrobenzoic acid), after preincubation with the inhibitor for 60 min at 37 °C. Hydrolysis of 1 mM acetylthiocholine was followed spectrophotometrically as described under "Experimental Procedures." Data points correspond to duplicates that differed by less than 5%. V/2, V/3, etc. indicate the points in the curve corresponding to the inhibitor concentration giving one-half, one-third, etc. of the enzyme activity measured without inhibitor. Dixon plots of rChII (A) and nFas2 (B) are shown.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   Lineweaver-Burk plots of E. electricus AChE at different concentrations of recombinant chimera II (A) and I (B), as indicated with acetylthiocholine. Data points represent the average value of two to three measurements differing by less than 5%.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   Upper panel, inhibition of human BuChE by native fasciculin 2 and recombinant chimeras I and II. Activities were measured in 1-ml reaction mixtures containing 50 mM phosphate buffer, pH 7.5, 0.1 mg/ml BSA, after preincubation with the inhibitor for 10 min at 37 °C. Hydrolysis of 1 mM of BTCh was followed spectrophotometrically as described under "Experimental Procedures." triangle , fasciculin 2; , chimera II; and open circle , chimera I. Lower left panel, Cornish-Bowden plots for inhibition of human BuChE by chimera II. The activity was assayed in 50 mM phosphate buffer, pH 7.5, 0.1 mg/ml BSA, with BTCh (0.1-0.5 mM) as substrate, and the incubation time was 10 min at 37 °C. The reactions were followed by the method of Ellman et al. (26), after the addition of the substrate. Lower right panel: Dixon plots 1/v versus chimera II for inhibition of human BuChE at different fixed concentrations of BTCh. The activity was assayed in the same conditions as mentioned in the Cornish-Bowden plots.

Structural Analysis of rChII-- In agreement with the results provided by circular dichroism, rChII adopts a typical three-fingered fold (Fig. 8). Indeed, the three-dimensional structure of rChII clearly demonstrates that most of its beta -sheet regions and disulfides superimpose well on those of fasciculin 2 and/or toxin alpha  (Fig. 8). Interestingly, the three-dimensional structure of rChII appears as a combination of specific structural features of fasciculins and short-chain toxins (53). For instance, loop 1 perfectly superimposed on loop 1 of fasciculin 2, as well as loop 2. In contrast, regions 16-21 and 55-57 are typically toxin alpha , with the presence of an additional proline in position 18 and a deletion between residues 56 and 57 in rChII. These two regions keep within the chimera a toxin alpha  fold. Finally, loop 3 has a toxin alpha  sequence but its conformation is probably triggered by the loop 2 orientation. It therefore appears that the nature of the sequence of loop 2 affects the overall conformation of the second beta -sheet. Interestingly, the part of loop 3 that corresponds to a fasciculin 2 fold is surrounded by two glycine residues at positions 39 and 48, respectively. This confirms the assumptions made concerning the need to preserve both the consensus sequences, which characterized the three-fingered fold, together with the secondary structure and loop organization typical of fasciculins. It also, emphasizes the great structural flexibility of that fold and how neatly the host toxin alpha  can structurally accommodate the imposed modifications. The detailed structural analysis of recombinant chimera II is presented and discussed in Le Du et al. (53). The coordinates of the rChII model have been deposited to the Protein Data Bank with entry code 1qm7.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 8.   Monographic views in ribbon representation of the three-dimensional structures of (a) toxin alpha  (blue), (b) fasciculin 2 (yellow), and (c) recombinant chimera II. Residues conserved between fasciculin 2, toxin alpha , and rChII are in green. Characteristic beta -sheets are indicated as large arrows.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Structural Deviations versus Functional Differences-- The aim of this paper was to explore the possibility that within a structurally related family of proteins, i.e. three-fingered toxins from snakes, subtle structural deviations could reflect the localization of a particular functional topographies. Clearly, our results strongly support that idea. Indeed, the fasciculin regions initially identified as differing most of toxin alpha  (r.m.s. deviations comprised between 2 and 13 Å) have now been neatly superimposed within rChII with an r.m.s. deviation less than 0.5 Å when compared with fasciculin 2 (53). Thus, loop 1 in its entirety now adopts the fold it displays in native fasciculins characterized in particular by longer beta -sheets and great mobility, because it occupies within rChII the conformation described for free fasciculin 2, which is also that of the bound state. Similarly, transferred residues 27-37 (toxin alpha  numbering) from loop 2 of fasciculins not only superimposed on the structure they have in native fasciculins but also constrained the conformation of adjacent residues. Finally, the typical inverse orientation of the tip of the central loop in fasciculins is found in rChII, which displays an opposite concavity to toxin alpha . These data are in total agreement with the recent elucidation of the structure of the complex formed between AChE showing that: i) AChE and Fas conformations in the complex are very similar to those of their isolated structures; ii) the high affinity of Fas for AChE is because of a remarkable surface complementarity involving many residues specific to fasciculins; iii) the first loop is responsible for the particular capacity of fasciculins to bind at the peripheral anionic site onto the surface of AChE; iv) loop 2 enters the AChE gorge because of its particular shape and orientation, allowing in particular an unusual stacking interaction between Met-33 (Fas) and Trp-279 (AChE), and finally that the C-terminal residues makes contact with the enzyme (21, 22).

Major structural deviations between short-chain neurotoxins and fasciculins clearly reflect their difference of biological activities. It has been recently shown that a more limited transfer of 7 of the 11 residues forming the curaremimetic site of toxin alpha  within a similar beta -sheet of charybdotoxin failed to generate a potent curaremitic agonist, mostly for conformational reasons (54). Therefore, to respect the structural integrity of the functional regions, we transferred 42.6% of specific residues (26 of 61 amino acid residues) from fasciculins into toxin alpha  mostly spread over two homogenous areas, i.e. loop 1 and half of the central loop. Thus, our results demonstrate that the structural deviations between short-chain neurotoxins and fasciculins and the location of their functional sites are intimately related. Indeed, substitution of structurally different regions actually confers on the host scaffold the expected biological activity, these heterologous segments containing most of the functionally important residues as experimentally identified, and transferred stretches keeping their native fold. This constitutes with the alpha /beta scorpion motif (55) a second example of the stability, structural flexibility, and functional adaptability of animal toxins, which are promising host scaffolds for protein engineering. Finally, we propose the identification of structure-based features as a convenient alternative way of guiding systematic mutations in the mapping of a functional epitope at the surface of biologically unrelated toxins adopting the same fold.

Evolutionary and Structural Considerations-- The choice of a short-chain curaremimetic as host scaffold was not arbitrary. We focused our study on three-fingered toxins whose target is a macromolecule, which is naturally recognized by the neurotransmitter acetylcholine. These toxins include short- and long-chain curaremimetic toxins, which block muscular nicotinic acetylcholine receptors, neuronal or muscarinic toxins, which act on neuronal or muscarinic receptors, respectively, and fasciculins, which inhibit acetylcholinesterases. Various studies suggest that these toxins are evolutionarily related (56), and a number of observations support the idea that they are derived from a curaremimetic toxin ancestor (57). Therefore, curaremimetic toxins and especially short-chain neurotoxins appeared as most plausible hosts to design three-fingered toxins with functionally distinct behaviors. Recent experimental data show that a long-chain neurotoxin, whose characteristic fifth disulfide bond was selectively reduced, behaves like a short-chain toxin in terms of specificity of receptor recognition (16). Furthermore, the addition of a fifth disulfide bound at the tip of the central loop of a short chain toxin increases its very low affinity for neuronal receptor (58). Similarly, our results demonstrate that a short-chain toxin can adopt mostly through "loop grafting," a totally unrelated biological activity toward a distinct target, and that this functional acquisition is structurally and functionally compatible with a conserved core of a different origin. Taken together, these data lend further support to the idea of an ancestor role of short-chain toxins in the phylogeny of three-fingered proteins.

Functional Properties of Recombinant Chimera-- Newly designed Tox alpha /Fas 2 recombinant chimeric molecules, and especially rChII, display biological properties and specificities that mimic almost completely those exhibited by native fasciculins. Recombinant chimeras I and II differ only by the point substitution: Asn or Tyr at position +61, respectively. However, despite this small difference, rChI is characterized by a 10 times lower inhibitory constant than rChII toward EaAChE. Our results confirm the importance played by the third point of contact between Fas and AChE, which involves a tyrosine cluster constituted of Tyr-4 and Tyr-61 side chains (21, 22) incomplete in chimera I, because the C-terminal Tyr-61 of fasciculins was missing. The C-terminal Tyr (conserved in fasciculins, but rare in other three-fingered toxins) is a structurally important residue involved in the position and orientation of the loops forming the functional site of Fas, resulting in an enlargement of the surface area of contact of loop II at the entrance of the AChE gorge. This strengthens the position of the loops of fasciculin 2 at the peripheral anionic site of the enzyme, leading to the sterical occlusion of the catalytic site. Finally, the C-terminal region of fasciculin 2 is stabilized by hydrogen bonds between the structurally important residue Arg-24 and the carbonyl atom of Tyr-61. Thus, the ten times lowest inhibitory activity of rChI toward EeAChE versus rChII confirms the structural and/or functional role played by the C terminus tyrosine residue in fasciculins. However, the significant noncompetitive inhibitory capacity nevertheless displayed by rChI toward EeAChE, together with its ability to inhibit human butyrylcholinesterase, strongly suggests that Tyr-61 most probably affects the affinity and not the specificity of these inhibitors for acetylcholinesterases.

Recombinant chimera II and native fasciculins display very similar but not identical biological properties. This is unlikely to be because of the strategy of bacterial expression and in vitro renaturation that may account for that situation, because rFas1 and denatured/renatured nFas1 have indistinguishable properties. Despite the simultaneous presence in rChII of the three major points of interaction previously described between fasciculin 2 and AChEs, rChII displays a slightly lower Ki value. Among the different explanations that may account for this, it has been postulated that the tip of the third loop in fasciculins (especially Asn-47 and Leu-48), establish an intramolecular interaction with the tip of loop 2 and could also be in close contact upon complexing with acetylcholinesterases (21, 22). It is noteworthy, that this region adopts an intermediate conformation in chimera II, as compared with toxin alpha  or fasciculin 2 (53). To assess the possibility that this remaining structural deviation could account for the weaker inhibitory capacity of rChII, a third chimera, in which the amino acid residues of the extremity of the third loop of Fasc 2 have been transferred, is being studied.

    ACKNOWLEDGEMENTS

We thank S. Pinkasfeld and Dr. F. Bouet for technical assistance and N-terminal sequencing. We also thank Dr. E. Quéméneur, and Dr. S. Zinn-Justin for their help and fruitful discussion. We are indebted to Dr. C. Cervenansky (Instituto de Investigaciones Biologicas, Clemente Estable, Montevideo, Uruguay) for his assistance.

    FOOTNOTES

* This work was supported in part by Evaluation-Orientation de la Coopération Scientifique, Program de Coopération Scientifique avec l'Uruguay.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and structure factors (code 1qm7) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

§ To whom correspondence should be addressed. Tel.: 33 1 69 08 8154; Fax: 33 1 69 08 9071.

    ABBREVIATIONS

The abbreviations used are: AChE, acetylcholinesterase; rFas, recombinant fasciculin; Fas, fasciculin; HPLC, high pressure liquid chromatography; EeAChE, E. electricus electroplax acetylcholinesterase; BSA, bovine serum albumin; BTCh, butyrylthiocholine; BuChE, butyrylcholinesterase; r.m.s., root mean square; ChI/II, chimera I/II; rCh, recombinant Ch; nFas, native Fas.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ménez, A. (1993) Pour la Science 190, 34-40
2. Endo, T., and Tamiya, N. (1991) in Snake Toxins (Harvey, A. L., ed) , pp. 165-222, Pergamon Press, New York
3. Walkinshaw, M. D., Saenger, W., and Maelicke, A. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 2400-2404[Abstract/Free Full Text]
4. Betzel, C., Lange, G., Pal, G. P., Wilson, K. S., Maelicke, A., and Saenger, W. (1991) J. Biol. Chem. 266, 21530-21536[Abstract/Free Full Text]
5. Oswald, R. E., Sutcliffe, M. J., Bamberger, M., Loring, R. H., Braswell, E., and Dobson, C. M. (1991) Biochemistry 30, 4901-4909[CrossRef][Medline] [Order article via Infotrieve]
6. Dewan, J. C., Grant, G. A., and Sacchettini, J. C. (1994) Biochemistry 33, 13147-13154[CrossRef][Medline] [Order article via Infotrieve]
7. Ségalas, I., Roumestand, C., Zinn-Justin, S., Gilquin, B., Ménez, R., Ménez, A., and Toma, F. (1995) Biochemistry 34, 1248-1260[CrossRef][Medline] [Order article via Infotrieve]
8. Cervenansky, C., Dajas, F., Harvey, A. L., and Karlsson, E. (1991) in Snake Toxins (Harvey, A. L., ed) , pp. 303-321, Pergamon Press, New York
9. Le Du, M. H., Marchot, P., Bougis, P. E., and Fontecilla-Camps, J. C. (1992) J. Biol. Chem. 267, 22122-22130[Abstract/Free Full Text]
10. Le Du, M. H., Housset, D., Marchot, P., Bougis, P. E., Navaza, J., and Fontecilla-Camps, J. C. (1996) Acta Crystallogr. Sec. D 52, 87-92[CrossRef][Medline] [Order article via Infotrieve]
11. Brown, L. R., and Wütrich, K. (1992) J. Mol. Biol. 227, 1118-1135[CrossRef][Medline] [Order article via Infotrieve]
12. Hatanaka, H., Oka, M., Kohda, D., Tate, S., Suda, A., Tamiya, N., and Inagaki, F. (1994) J. Mol. Biol. 240, 155-166[CrossRef][Medline] [Order article via Infotrieve]
13. Albrand, J. P., Blackledge, M. J., Pascaud, F., Hollecker, M., and Marion, D. (1995) Biochemistry 34, 5923-5937[CrossRef][Medline] [Order article via Infotrieve]
14. Ménez, A., Bontems, F., Roumestand, C., Gilquin, B., and Toma, F. (1992) in The Advancement of Drug Discovery (Harvey, A. L., ed) , pp. 83-103, Royal Society of Edinburg
15. Ohno, M., Ménez, R., Ogawa, T., Danse, J. M., Shimohigashi, Y., Fromen, C., Ducancel, F., Zinn-Justin, S., Le Du, M. H., Boulain, J. C., Tamiya, T., and Ménez, A. (1998) Prog. Nucleic Acid Res. Mol. Biol. 59, 307-364[Medline] [Order article via Infotrieve]
16. Servent, D., Winckler-Dietrich, V., Hu, H. Y., Kessler, P., Drevet, P., Bertrand, D., and Ménez, A. (1997) J. Biol. Chem. 272, 24279-24286[Abstract/Free Full Text]
17. Chang, C. C. (1979) in Snake Venoms, Handbook of Experimental Pharmacology (Lee, C. Y., ed), Vol. 52 , pp. 309-376, Springer-Verlag, Berlin
18. Rodriguez-Ithuralde, D., Silveira, R., Barbeito, L., and Dajas, F. (1983) Neurochem. Int. 5, 267-274
19. Pillet, L., Trémeau, O., Ducancel, F., Drevet, P., Zinn-Justin, S., Pinkasfeld, S., Boulain, J. C., and Ménez, A. (1993) J. Biol. Chem. 268, 909-916[Abstract/Free Full Text]
20. Trémeau, O., Lemaire, C., Drevet, P., Pinkasfeld, S., Ducancel, F., Boulain, J. C., and Ménez, A. (1995) J. Biol. Chem. 270, 9362-9369[Abstract/Free Full Text]
21. Bourne, Y., Taylor, P., and Marchot, P. (1995) Cell 83, 503-512[CrossRef][Medline] [Order article via Infotrieve]
22. Harel, M., Kleywegt, G. J., Ravelli, R. B. G., Silman, I., and Sussman, J. L. (1995) Structure 3, 1355-1366[Medline] [Order article via Infotrieve]
23. Drevet, P., Lemaire, C., Gasparini, S., Zinn-Justin, S., Lajeunesse, E., Ducancel, F., Pinkasfeld, S., Courçon, M., Trémeau, O., Boulain, J. C., and Ménez, A. (1997) Protein Expression Purif. 10, 293-300[CrossRef][Medline] [Order article via Infotrieve]
24. Nilsson, B., Moks, T., Jansson, B., Abrahmsen, L., Elmbllad, A., Holmgren, E., Henrichson, C., Jones, T. A., and Uhlen, M. (1987) Protein Eng. 1, 107-113[Abstract/Free Full Text]
25. Boulain, J. C., Ménez, A., Couderc, J., Faure, G., Liacopoulos, P., and Fromageot, P. (1982) Biochemistry 21, 2910-2915[CrossRef][Medline] [Order article via Infotrieve]
26. Ellman, G. L., Courtney, K. D., Andres, V., and Featherstone, R. M. (1961) Biochem. Pharmacol. 7, 88-95[CrossRef][Medline] [Order article via Infotrieve]
27. Dixon, M. (1972) Biochem J. 129, 197-202[Medline] [Order article via Infotrieve]
28. Karlsson, E., Mbugua, P. M., and Rodriguez-Ithurralde, D. (1984) J. Physiol. (Paris) 79, 232-240[Medline] [Order article via Infotrieve]
29. Duran, R., Cervenansky, C., Dajas, F., and Tipton, K. (1994) Biochim. Biophys. Acta 1201, 381-388[Medline] [Order article via Infotrieve]
30. Cornish-Bowden, A. (1974) Biochem J. 137, 143-144[Medline] [Order article via Infotrieve]
31. Satow, Y., Cohen, G. H., Padlan, E. A., and Davies, D. R. (1986) J. Mol. Biol. 190, 593-604[CrossRef][Medline] [Order article via Infotrieve]
32. Guenneugues, M., Drevet, P., Pinkasfeld, S., Gilquin, B., Ménez, A., and Zinn-Justin, S. (1997) Biochemistry 36, 16097-16108[CrossRef][Medline] [Order article via Infotrieve]
33. Ducancel, F., Bouchier, C., Tamiya, T., Boulain, J. C., and Ménez, A. (1991) in Snake Toxins (Harvey, A. L., ed) , pp. 385-414, Pergamon Press, New York
34. Eaker, D., and Porath, J. (1967) J. Microbiol. (Japan) 11, 353-355
35. Zinn-Justin, S., Roumestand, C., Gilquin, B., Bontems, F., Ménez, A., and Toma, F. (1992) Biochemistry 31, 11335-11347[CrossRef][Medline] [Order article via Infotrieve]
36. Minor, D. L., Jr., and Kim, P. S. (1996) Nature 380, 730-734[CrossRef][Medline] [Order article via Infotrieve]
37. Lobeck, K., Drevet, P., Léonetti, M., Fromen-Romano, C., Ducancel, F., Lajeunesse, E., Lemaire, C., and Ménez, A. (1998) Infect. Immun. 66, 418-423[Abstract/Free Full Text]
38. Hodgson, D., Gasparini, S., Drevet, P., Ducancel, F., Bouet, F., Boulain, J. C., Harris, J. B., and Ménez, A. (1993) Eur. J. Biochem. 212, 441-446[Medline] [Order article via Infotrieve]
39. Danse, J. M., Rowan, E. G., Gasparini, S., Ducancel, F., Vatanpour-Young, L. C., Poorheidari, G., Lajeunesse, E., Drevet, P., Ménez, R., Pinkasfeld, S., Boulain, J. C., Harvey, A. L., and Ménez, A. (1994) FEBS Lett. 356, 153-158[CrossRef][Medline] [Order article via Infotrieve]
40. Fiordalisi, J. J., Al-Rabiee, R., Chiappinelli, V. A., and Grant, G. A. (1994) Biochemistry 33, 3872-3877[CrossRef][Medline] [Order article via Infotrieve]
41. Bouhaouala-Zahar, B., Ducancel, F., Zenouaki, I., Khalifa, R. B., Boorchani, L., Pelhate, M., Boulain, J. C., El Ayeb, M., Ménez, A., and Karoui, H. (1996) Eur. J. Biochem. 238, 653-660[Medline] [Order article via Infotrieve]
42. Ducancel, F., Boulain, J. C., Trémeau, O., and Ménez, A. (1989) Protein Eng. 3, 139-143[Abstract/Free Full Text]
43. Boyot, P., Pillet, L., Ducancel, F., Boulain, J. C., Trémeau, O., and Ménez, A. (1990) FEBS Lett. 266, 87-90[CrossRef][Medline] [Order article via Infotrieve]
44. LaVallie, E. R., DiBlasio, E. A., Kovacic, S., Grant, K. L., Schendel, P. F., and McCoy, J. M. (1993) Bio/Technology 11, 187-193[CrossRef][Medline] [Order article via Infotrieve]
45. Vozza, L. A., Wittwer, L., Higgins, D. R., Purcell, T. J., Bergseid, M., Collins-Racie, L. A., LaVallie, E. R., and Hoeffler, J. P. (1996) Bio/Technology 14, 77-81[CrossRef][Medline] [Order article via Infotrieve]
46. Ruoppolo, M., Moutiez, M., Mazzeo, M. F., Pucci, P., Ménez, A., Marino, G., and Quéméneur, E. (1998) Biochemistry 37, 16060-16068[CrossRef][Medline] [Order article via Infotrieve]
47. Weber, M., and Changeux, J. P. (1974) Mol. Pharmacol. 10, 1-14[Abstract/Free Full Text]
48. Boulain, J. C., and Ménez, A. (1982) Science 217, 732-733[Abstract/Free Full Text]
49. Trémeau, O., Boulain, J. C., Couderc, J., Fromageot, P., and Ménez, A. (1986) FEBS Lett. 208, 236-240[CrossRef][Medline] [Order article via Infotrieve]
50. Zinn-Justin, S., Pillet, L., Ducancel, F., Thomas, A., Smith, J. C., Boulain, J. C., and Ménez, A. (1994) Protein Eng. 7, 917-923[Abstract/Free Full Text]
51. Ducancel, F., Mérienne, K., Fromen-Romano, C., Trémeau, O., Pillet, L., Drevet, P., Zinn-Justin, S., Boulain, J. C., and Ménez, A. (1996) J. Biol. Chem. 271, 31345-31353[Abstract/Free Full Text]
52. Masson, P., Froment, M. T., Bartels, C. F., and Lockridge, O. (1996) Eur. J. Biochem. 235, 36-48[Medline] [Order article via Infotrieve]
53. Le Du, M. H., Ricciardi, A., Khayati, M., Ménez, R., Boulain, J. C., Ménez, A., and Ducancel, F. (2000) J. Mol. Biol. 296, 1017-1026[CrossRef][Medline] [Order article via Infotrieve]
54. Drakopoulou, E., Zinn-Justin, S., Guenneugues, M., Gilquin, B., Ménez, A., and Vita, C. (1996) J. Biol. Chem. 271, 11979-11987